CBD oil improved autistic behaviors and reduced brain oxidative stress in a mouse model | Research

The takeaway

In mice with valproic acid-induced autism-like behavior, three weeks of CBD oil treatment improved social interaction, reduced anxiety, and lowered oxidative stress in the brain.

Autism researchers, pediatric neurologists, CBD pharmacology researchers

CBD oil performed comparably to risperidone in autism mouse model

What the researchers found

In a valproic acid-induced autism mouse model, CBD oil (100 mg/kg/day orally for 3 weeks starting at postnatal day 21) improved autistic behaviors including anxiety, delayed response to painful stimuli, and impaired social interaction. Biochemical analysis showed CBD oil restored depleted glutathione and antioxidant levels. Morphological staining revealed improvements in the hippocampus, prefrontal cortex, and Purkinje cells. CBD oil performed comparably to the standard antipsychotic risperidone (0.5 mg/kg/day).

Why it matters

Autism spectrum disorder currently has no effective treatment for core symptoms. Preclinical evidence that CBD oil addresses both behavioral and neurobiological aspects of autism through antioxidant mechanisms could inform future clinical research, though animal models of autism have significant translational limitations.

The numbers in context

CBD oil 100 mg/kg/day for 3 weeks; VPA 600 mg/kg gestational exposure; compared to risperidone 0.5 mg/kg/day; improvements in hippocampus, prefrontal cortex, and Purkinje cells

How the study worked

VPA-induced autism mouse model using BALB/c mice exposed to valproic acid (600 mg/kg) on gestational day 13. Male pups divided at postnatal day 21 into four groups: control saline, VPA-exposed, VPA + CBD oil (100 mg/kg/day), and VPA + risperidone (0.5 mg/kg/day) for 3 weeks. Behavioral, biochemical, and histological analyses performed.

What this study cannot tell us

Animal model of autism has significant limitations in replicating human ASD. Only male pups studied. Single dose of CBD oil tested. VPA-induced autism model represents only one possible etiology. Short treatment duration. Translating mouse doses to human equivalents is uncertain.

How to read the evidence

Well-controlled animal study with multiple outcome measures and a standard comparator, but VPA-induced autism model has limited translational validity for human ASD.

When this study was published

2025 publication

The bigger picture

Interest in cannabidiol for autism has grown rapidly, with some clinical trials underway. This preclinical study suggests the mechanism may involve antioxidant pathways rather than direct cannabinoid receptor effects, which could guide clinical trial design and outcome measures.

Questions still open

Would CBD oil show similar effects in other autism animal models with different etiologies? Do the antioxidant mechanisms observed translate to measurable biomarkers in human autism trials?

Common questions

Does this mean CBD can treat autism in humans?

No. This is an animal study using a specific mouse model of autism. While the results are encouraging, mouse models of autism have significant limitations, and clinical trials in humans are needed before any conclusions about human treatment can be drawn.

How did CBD compare to a standard medication?

CBD oil (100 mg/kg/day) showed comparable improvements to risperidone (0.5 mg/kg/day), a standard antipsychotic used for autism-related irritability, in behavioral and biochemical measures.

Read the original research

Cannabis Oil Protects Against Valproic Acid-Induced Autism Spectrum Disorder by Reducing Oxidative Stress.

Developmental neurobiology, 85(3), e22969

View on PubMed ↗Publisher’s paper ↗

Citation

Ali, Faiza; Shehzad, Adeeb; Shahzad, Raheem; Khan, Salman; Rashan, Luay; Taha, Muhammad. (2025). Cannabis Oil Protects Against Valproic Acid-Induced Autism Spectrum Disorder by Reducing Oxidative Stress.. Developmental neurobiology, 85(3), e22969. https://doi.org/10.1002/dneu.22969